US8097648B2
(en)
*
|
1998-06-17 |
2012-01-17 |
Eisai R&D Management Co., Ltd. |
Methods and compositions for use in treating cancer
|
IL139960A0
(en)
|
1998-06-17 |
2002-02-10 |
Eisai Co Ltd |
Macrocylic analogs and methods of their use and preparation
|
US6653341B1
(en)
*
|
1998-06-17 |
2003-11-25 |
Eisai Co., Ltd. |
Methods and compositions for use in treating cancer
|
DE10037310A1
(en)
|
2000-07-28 |
2002-02-07 |
Asta Medica Ag |
New indole derivatives and their use as medicines
|
EP1531846A4
(en)
*
|
2002-02-27 |
2006-04-19 |
Us Gov Health & Human Serv |
Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
|
JP5042444B2
(en)
|
2002-03-22 |
2012-10-03 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Hemiasterine derivatives and their use in the treatment of cancer
|
US20050075395A1
(en)
*
|
2003-05-28 |
2005-04-07 |
Gary Gordon |
Continuous dosing regimen
|
EP1644008B1
(en)
*
|
2003-05-29 |
2011-12-21 |
Abbott Laboratories |
Continuous dosing regimen with abt-751
|
EP1653953A4
(en)
*
|
2003-07-29 |
2010-05-05 |
Eisai R&D Man Co Ltd |
Drug delivery methods and devices
|
CA2935786C
(en)
|
2004-06-03 |
2019-02-12 |
Eisai R & D Management Co., Ltd. |
Intermediates for the preparation of analogs of halichondrin b
|
CN109180615A
(en)
*
|
2004-06-03 |
2019-01-11 |
卫材R&D管理有限公司 |
It is used to prepare the intermediate of the analog of halichondrin B
|
US20060045846A1
(en)
*
|
2004-08-30 |
2006-03-02 |
Horstmann Thomas E |
Reagents and methods for labeling terminal olefins
|
US20060154312A1
(en)
*
|
2004-12-09 |
2006-07-13 |
Sergei Agoulnik |
Tubulin isotype screening in cancer therapy using halichondrin B analogs
|
MX2010003599A
(en)
|
2007-10-03 |
2010-09-10 |
Eisai R&D Man Co Ltd |
Intermediates and methods for the synthesis of halichondrin b analogs.
|
RU2517167C2
(en)
|
2008-04-04 |
2014-05-27 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Halichondrin b analogues
|
WO2010113984A1
(en)
|
2009-03-30 |
2010-10-07 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Liposome composition
|
US9968583B2
(en)
|
2009-03-30 |
2018-05-15 |
Eisai R & D Management Co., Ltd. |
Method of manufacture of liposome composition
|
RU2476216C1
(en)
*
|
2009-03-30 |
2013-02-27 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Liposomal composition
|
CN102421782B
(en)
*
|
2009-04-14 |
2015-04-22 |
日产化学工业株式会社 |
Method for producing tetrahydropyran compound and intermediate thereof
|
CN102803254B
(en)
|
2010-01-26 |
2016-09-14 |
卫材R&D管理有限公司 |
Furo [3,2-B] pyran derivate for halichondrin b analogs synthesis
|
WO2012129100A1
(en)
|
2011-03-18 |
2012-09-27 |
Eisai R&D Management Co., Ltd. |
Methods and compositions for predicting response to eribulin
|
WO2012147900A1
(en)
|
2011-04-28 |
2012-11-01 |
Eisai R&D Management Co., Ltd. |
Microreactor process for halichondrin b analog synthesis
|
WO2012166899A2
(en)
|
2011-06-03 |
2012-12-06 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
AU2012344697A1
(en)
|
2011-11-30 |
2014-07-10 |
Alphora Research Inc. |
Process for preparation of (3R)-2,4-di-leaving group-3-methylbut-1-ene
|
JP2015501818A
(en)
|
2011-12-16 |
2015-01-19 |
アルフォラ リサーチ インコーポレイテッドAlphora Research Inc. |
Process for preparing 3-((2S, 5S) -4-methylene-5- (3-oxopropyl) tetrahydrofuran-2-yl) propanol derivatives and useful intermediates thereof
|
IN2014MN01521A
(en)
*
|
2011-12-29 |
2015-05-01 |
Alphora Res Inc |
|
AU2013239290B2
(en)
|
2012-03-30 |
2017-08-03 |
Sandoz Ag |
Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein
|
AU2013353745A1
(en)
|
2012-12-04 |
2015-06-11 |
Eisai R&D Management Co., Ltd. |
Use of eribulin in the treatment of breast cancer
|
CA2909209A1
(en)
|
2013-05-15 |
2014-11-20 |
Alphora Research Inc. |
3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof
|
CN105338977B
(en)
|
2013-06-26 |
2018-10-16 |
卫材R&D管理有限公司 |
Eribulin and the happy purposes cut down for Buddhist nun as the conjoint therapy for the treatment of cancer
|
CN105431438A
(en)
*
|
2013-07-03 |
2016-03-23 |
阿方拉研究股份有限公司 |
Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups
|
CN103483352A
(en)
*
|
2013-10-18 |
2014-01-01 |
李友香 |
Medicinal bulk drug for resisting tumors
|
EP3066102B1
(en)
|
2013-11-04 |
2020-02-26 |
Eisai R&D Management Co., Ltd. |
Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b
|
SG11201604545XA
(en)
|
2013-12-06 |
2016-07-28 |
Eisai R&D Man Co Ltd |
Methods useful in the synthesis of halichondrin b analogs
|
CN104860978A
(en)
*
|
2014-02-20 |
2015-08-26 |
正大天晴药业集团股份有限公司 |
Synthesis intermediates of halichondrin B analog
|
TW201617326A
(en)
|
2014-03-06 |
2016-05-16 |
Alphora研發股份有限公司 |
Crystalline derivatives of (S)-1-((2R,3R,4S,5S)-5-allyl-3-methoxy-4-(tosylmethyl)tetrahydrofuran-2-yl)-3-aminopropan-2-ol
|
CA2950320A1
(en)
|
2014-05-28 |
2015-12-03 |
Eisai R&D Management Co., Ltd |
Use of eribulin in the treatment of cancer
|
WO2016003975A1
(en)
|
2014-06-30 |
2016-01-07 |
President And Fellows Of Harvard College |
Synthesis of halichondrin analogs and uses thereof
|
RS63559B1
(en)
|
2014-08-28 |
2022-10-31 |
Eisai R&D Man Co Ltd |
High-purity quinoline derivative and method for manufacturing same
|
US10208058B2
(en)
|
2014-09-09 |
2019-02-19 |
Cipla Limited |
Process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts and intermediates thereof
|
CN105713031B
(en)
*
|
2014-12-05 |
2021-05-07 |
正大天晴药业集团股份有限公司 |
Intermediate for preparing eribulin and preparation method thereof
|
PL3263106T3
(en)
|
2015-02-25 |
2024-04-02 |
Eisai R&D Management Co., Ltd. |
Method for suppressing bitterness of quinoline derivative
|
AU2015384801B2
(en)
|
2015-03-04 |
2022-01-06 |
Eisai R&D Management Co., Ltd. |
Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
|
MX2017011206A
(en)
|
2015-03-04 |
2018-05-17 |
Merck Sharp & Dohme |
Combination of a pd-1 antagonist and eribulin for treating cancer.
|
WO2016176560A1
(en)
|
2015-04-30 |
2016-11-03 |
President And Fellows Of Harvard College |
Chromium-mediated coupling and application to the synthesis of halichondrins
|
CN117024469A
(en)
*
|
2015-05-07 |
2023-11-10 |
卫材R&D管理有限公司 |
Macrocyclization reactions useful for the synthesis of halichondrin macrolides, intermediates and other fragments
|
US10597401B2
(en)
|
2015-05-08 |
2020-03-24 |
Albany Molecular Research, Inc. |
Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
|
BR112017027227B1
(en)
|
2015-06-16 |
2023-12-12 |
Eisai R&D Management Co., Ltd |
ANTI-CANCER AGENT
|
EP3413887B1
(en)
|
2016-02-12 |
2021-04-07 |
Eisai R&D Management Co., Ltd. |
Intermediates in the synthesis of eribulin and related methods of synthesis
|
WO2017188350A1
(en)
|
2016-04-28 |
2017-11-02 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Method for inhibiting tumor growth
|
CN109415383A
(en)
*
|
2016-05-26 |
2019-03-01 |
雷迪博士实验室有限公司 |
Prepare the method and its intermediate of eribulin
|
KR102404629B1
(en)
|
2016-06-30 |
2022-06-02 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
Prince Reaction and Intermediates Useful for Synthesis of Halicondine Macrolides and Analogs thereof
|
WO2018071792A1
(en)
|
2016-10-14 |
2018-04-19 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
|
JP6978758B2
(en)
|
2016-11-11 |
2021-12-08 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
Palladium-mediated ketolization
|
BR112019010494A2
(en)
|
2016-11-23 |
2019-09-17 |
Dr Reddys Laboratories Ltd |
process for the preparation of eribulin and intermediates thereof
|
KR101880939B1
(en)
|
2017-01-02 |
2018-08-17 |
연성정밀화학(주) |
Intermediate for Preparing Eribulin Mesylate and Process for Preapring the Same
|
EP3564243B1
(en)
|
2017-01-02 |
2022-11-09 |
Yonsung Fine Chemical Co., Ltd. |
Production intermediate of eribulin mesylate, and method for producing same
|
KR101991710B1
(en)
|
2017-12-14 |
2019-06-21 |
연성정밀화학(주) |
Intermediate for Preparing Eribulin Mesylate and Process for Preparing the Same
|
CN108341828B
(en)
*
|
2017-01-24 |
2021-04-06 |
江苏恒瑞医药股份有限公司 |
Process for the preparation of eribulin and intermediates thereof
|
CN108341738B
(en)
*
|
2017-01-24 |
2022-10-21 |
江苏恒瑞医药股份有限公司 |
Process for the preparation of eribulin and intermediates thereof
|
SG11201908603PA
(en)
|
2017-04-05 |
2019-10-30 |
Harvard College |
Macrocyclic compound and uses thereof
|
US9938288B1
(en)
|
2017-04-05 |
2018-04-10 |
President And Fellows Of Harvard College |
Macrocyclic compound and uses thereof
|
US11498892B2
(en)
|
2017-07-06 |
2022-11-15 |
President And Fellows Of Harvard College |
Fe/Cu-mediated ketone synthesis
|
SG11201912342QA
(en)
|
2017-07-06 |
2020-01-30 |
Harvard College |
Synthesis of halichondrins
|
US20190046513A1
(en)
|
2017-08-10 |
2019-02-14 |
Huya Bioscience International, Llc |
Combination therapies of hdac inhibitors and tubulin inhibitors
|
CN109694379B
(en)
*
|
2017-10-24 |
2020-09-11 |
江苏恒瑞医药股份有限公司 |
Intermediate for preparing eribulin and preparation method thereof
|
US11142509B2
(en)
|
2017-11-09 |
2021-10-12 |
Yonsung Fine Chemical Co., Ltd. |
Intermediate for preparing eribulin mesylate and process for preparing the same
|
CN117924310A
(en)
|
2017-11-15 |
2024-04-26 |
哈佛大学的校长及成员们 |
Macrocyclic compounds and uses thereof
|
EP3713565A1
(en)
|
2017-11-20 |
2020-09-30 |
Basilea Pharmaceutica International AG |
Pharmaceutical combinations for use in the treatment of neoplastic diseases
|
US11008296B2
(en)
|
2017-11-21 |
2021-05-18 |
Natco Pharma Limited |
Intermediates for the preparation of eribulin thereof
|
EP3737673B1
(en)
|
2018-01-03 |
2024-03-06 |
Eisai R&D Management Co., Ltd. |
Process for preparing halichondrin macrolides and analogs thereof by a prins reaction, and intermediates of this process
|
WO2019211877A1
(en)
|
2018-05-03 |
2019-11-07 |
Cipla Limited |
Process for the preparation of macrocyclic ketone analogs of halichondrin b
|
WO2020008382A1
(en)
*
|
2018-07-04 |
2020-01-09 |
Dr. Reddy’S Laboratories Limited |
Process for preparation of eribulin and intermediates thereof
|
US20210260023A1
(en)
*
|
2018-07-20 |
2021-08-26 |
Dr. Reddy's Laboratories Limited |
Purification process for preparation of eribulin and intermediates thereof
|
WO2020075027A1
(en)
*
|
2018-10-09 |
2020-04-16 |
Dr. Reddy's Laboratories Limited |
Process for preparation of eribulin and intermediates thereof
|
US11447499B2
(en)
|
2019-06-14 |
2022-09-20 |
Rk Pharma Inc. |
Process for the preparation of eribulin mesylate intermediate
|
JP2022537785A
(en)
|
2019-06-21 |
2022-08-29 |
カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ |
Chemoenzymatic process for preparing homopropargyl alcohol
|
US11083705B2
(en)
|
2019-07-26 |
2021-08-10 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
BR112022008756A2
(en)
|
2019-11-07 |
2022-07-26 |
Eisai R&D Man Co Ltd |
ANTI-MESOTHELIN ERIBULIN ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
|
CN113135876B
(en)
*
|
2020-01-16 |
2024-05-17 |
南通诺泰生物医药技术有限公司 |
Preparation method of eribulin and intermediate thereof
|
BR112022014398A2
(en)
*
|
2020-01-22 |
2022-09-13 |
Shanghai Senhui Medicine Co Ltd |
ERIBULIN DERIVATIVE DRUG CONJUGATE, METHOD OF PREPARATION FOR IT AND APPLICATION OF IT IN MEDICINE
|
KR102377262B1
(en)
|
2020-05-11 |
2022-03-22 |
연성정밀화학(주) |
Crystalline Eribulin Salt
|
IL279168B
(en)
*
|
2020-12-02 |
2022-04-01 |
Finetech Pharmaceutical Ltd |
Process for the preparation of eribulin
|
CN113354659B
(en)
|
2021-06-08 |
2022-04-08 |
江苏慧聚药业股份有限公司 |
Synthesis of eribulin mesylate
|
CA3225975A1
(en)
*
|
2021-07-22 |
2023-01-26 |
Shanghai Senhui Medicine Co., Ltd. |
Drug conjugate of eribulin derivative
|
WO2023212746A2
(en)
*
|
2022-04-30 |
2023-11-02 |
William Marsh Rice University |
A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin b
|